search

Active clinical trials for "Neoplasm, Residual"

Results 31-40 of 174

Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive...

Acute Lymphoblastic LeukemiaB Acute Lymphoblastic Leukemia1 more

This phase II trial studies how well inotuzumab ozogamicin works in treating patients with B-cell acute lymphocytic leukemia with positive minimal residual disease. Inotuzumab ozogamicin is a monoclonal antibody called inotuzumab linked to a toxic agent called ozogamicin. Inotuzumab ozogamicin attaches to B cell-specific CD22 cancer cells in a targeted way and kills them.

Recruiting15 enrollment criteria

A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION...

Colon CancerResected Stage

A study of immunotherapy with expanded CB-NK cells in combination with cetuximab, to evaluate activity against minimal residual disease in patients with colon cancer that have completed adjuvant treatment but are positive for ctDNA

Recruiting63 enrollment criteria

Adjuvant Durvalumab for Early Stage NSCLC Patients With ctDNA Minimal Residual Disease

Non-small Cell Lung CancerNon-small Cell Lung Cancer Stage I2 more

In this study circulating tumor DNA (ctDNA) blood testing is used to detect the residual blood cancer. If residual cancer using this blood test is detected there may be at higher risk of having the cancer return. The study is going to test whether or not the number of circulating cancer cells detected in the blood can be reduced by administration durvalumab after the standard treatment if you are tested positive for the residual cancer.

Recruiting54 enrollment criteria

Evaluation of 3D Ultrasound in Brain Tumor Surgery

Residual Tumor

Evaluation of impact of use of 3D ultrasound in brain tumor surgery on extend of resection. Benefit for surgery, neurological outcome, accuracy and image quality are secondary outcome parameters. Control group is a retrospective matched pair cohort.

Recruiting2 enrollment criteria

Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD

Acute Lymphoblastic Leukemiain Relapse2 more

Various drugs have been added to different treatment regimens in order to improve the response rate in patients with Acute Lymphoblastic Leukemia, however, it has been shown that adding Bortezomib to the relapsing regimen improves the proportion of second complete remissions without increasing chemotherapy toxicity. Therefore, proteasome inhibitors can drastically modify the prognosis of patients, since their synergy with drugs such as steroids has positioned them as an attractive strategy.

Recruiting8 enrollment criteria

DAILY: Vitamin D, Aspirin, ExercIse, Low Saturated Fat Foods StudY in Colorectal Cancer Patients...

Colorectal CancerColon Cancer

To learn if lifestyle changes (such as diet and exercise) combined with daily aspirin and vitamin D can affect the likelihood of advanced colorectal cancer coming back (recurring)

Recruiting18 enrollment criteria

Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People...

Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)

This study will find out whether people with CLL or SLL who have received treatment with venetoclax, either alone or in combination with another drug, and who are found to be MRD-negative, can stop treatment with venetoclax and remain off-treatment for 12 months or more. The researchers will also see whether study participants remain MRD-negative after they stop treatment with venetoclax.

Recruiting18 enrollment criteria

Pre-emptive Daratumumab Therapy of Minimal Residual Disease Reappearance or Biochemical Relapse...

Multiple Myeloma

PREDATOR is a study investigating a role of preemptive daratumumab therapy for preclinical relapse or progression of multiple myeloma (MM).

Recruiting68 enrollment criteria

Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations...

Lymphoma

To test the feasibility of collecting cell-free DNA (cfDNA) samples from DLBCL patients before and after treatment. cfDNA is DNA traveling in your blood outside of a cell and is easily collected from blood samples drawn using the vein puncture method.

Recruiting6 enrollment criteria

Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual...

Adult Acute Lymphoblastic Leukemia in Complete RemissionB Acute Lymphoblastic Leukemia2 more

This phase II trial studies how well blinatumomab works in treating patients with B-cell acute lymphoblastic leukemia whose disease is in remission (causes no symptoms or signs) but is still present in a small number of cells in the body (minimal residual disease). Immunotherapy with monoclonal antibodies, such as blinatumomab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread.

Active14 enrollment criteria
1...345...18

Need Help? Contact our team!


We'll reach out to this number within 24 hrs